Prescient Therapeutics Ltd (ASX: PTX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Prescient Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $35.43 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 805.32 million
Earnings per share -0.010
Dividend per share N/A
Year To Date Return -29.03%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Prescient Therapeutics Ltd (ASX: PTX)
    Latest News

    medical asx share price represented by doctor giving thumbs up
    Healthcare Shares

    Guess which ASX biotech stock just rocketed 29% on big FDA news

    The ASX healthcare share is attracting investor interest following FDA approval for its targeted cancer therapy compound.

    Read more »

    PTX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Prescient Therapeutics Ltd

    Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

    PTX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 May 2024 $0.04 $0.00 0.00% 411,146 $0.04 $0.04 $0.04
    23 May 2024 $0.04 $0.00 0.00% 290,368 $0.05 $0.05 $0.04
    22 May 2024 $0.05 $0.00 0.00% 585,253 $0.05 $0.05 $0.04
    21 May 2024 $0.05 $0.00 0.00% 861,847 $0.05 $0.05 $0.05
    20 May 2024 $0.05 $0.00 0.00% 1,601,993 $0.04 $0.05 $0.04
    17 May 2024 $0.04 $0.00 0.00% 416,982 $0.04 $0.04 $0.04
    16 May 2024 $0.04 $0.00 0.00% 400,529 $0.04 $0.05 $0.04
    15 May 2024 $0.04 $0.00 0.00% 845,400 $0.04 $0.05 $0.04
    14 May 2024 $0.04 $0.00 0.00% 363,655 $0.04 $0.04 $0.04
    13 May 2024 $0.04 $0.00 0.00% 570,972 $0.04 $0.04 $0.04
    10 May 2024 $0.04 $0.00 0.00% 775,235 $0.04 $0.04 $0.04
    09 May 2024 $0.04 $0.00 0.00% 2,375,833 $0.04 $0.04 $0.04
    08 May 2024 $0.04 $0.00 0.00% 1,310,235 $0.05 $0.05 $0.04
    07 May 2024 $0.05 $0.00 0.00% 1,964,562 $0.05 $0.05 $0.04
    06 May 2024 $0.05 $0.00 0.00% 2,157,075 $0.05 $0.05 $0.05
    03 May 2024 $0.05 $0.00 0.00% 2,033,288 $0.05 $0.05 $0.05
    02 May 2024 $0.05 $0.00 0.00% 553,602 $0.05 $0.05 $0.05
    01 May 2024 $0.05 $0.00 0.00% 440,054 $0.05 $0.05 $0.05
    30 Apr 2024 $0.05 $0.00 0.00% 858,616 $0.05 $0.05 $0.05
    29 Apr 2024 $0.05 $0.00 0.00% 762,848 $0.05 $0.06 $0.05
    26 Apr 2024 $0.05 $-0.01 -17.24% 1,126,758 $0.06 $0.06 $0.05

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr James Campbell Non-Executive Director Nov 2014
    Dr Campbell has more than 20 years of international biotechnology research, management and leadership experience and has been involved in the creation and/or transformation of multiple Australian and international biotechnology companies. Dr Campbell was a foundation executive of Evolve Biosystems, and has assisted private biotechnology companies in Australia, New Zealand and the USA with capital raising and partnering negotiations. He is Chair of Risk Committee.
    Mr Steven Yatomi-Clarke Chief Executive OfficerManaging Director Nov 2014
    Mr Yatomi-Clarke manages a team in Australia and the US and has been involved in strategy development, licensing; initiating and managing clinical trials; identifying research directions and pre-clinical research design; fundraising and business development. He has over 17 years of experience in investment banking specializing in healthcare and biotechnology, where he was consistently one of the most prolific and successful bankers, involved in primary and secondary offerings, corporate advisory and mergers and acquisitions assignments for pharmaceutical and medical device companies.
    Mr Steven (Steve) Barnard Engle Non-Executive ChairmanNon-Executive Director Nov 2014
    Mr Engle is a resident of the US and has over two decades of executive leadership experience with public and private biotechnology companies developing breakthrough products in metabolic, autoimmune, oncologic, and infectious disease areas. Mr. Engle is the CEO and an Executive Director of Gradalis Inc., a late-stage biopharmaceutical company focused on the development and commercialization of personalized therapeutics to treat cancer. He is member of the board of AROA Biosurgery, a marketer and developer of regenerative products, and Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. Steve also leads Averigon, an advisory firm to the life sciences industry. He is also member of the Risk Committee.
    Dr Allen James Ebens Non-Executive Director Jun 2020
    Dr Ebens is Chief Science Officer at Vera Therapeutics, a San Francisco California based biotechnology company. Dr Ebens is a drug developer, having overseen the advancement of multiple drug development projects from concept to clinical development including polatuzumab, which is approved by the US FDA and is now marketed for use in diffuse large B-cell lymphoma.
    Dr Ellen Gwen Feigal Non-Executive Director May 2023
    Dr Feigal is currently a Partner and Head of the Biologics practice at global life sciences advisory firm, NDA Partners LLC, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology, and oncology. She is also adjunct faculty at the Sandra Day O'Connor College of Law, Arizona State University, where she teaches FDA drug law and medical research ethics and law.
    Ms Melanie Jaye Leydin Chief Financial OfficerCompany Secretary Feb 2015
    -
    Melanie Jaye Leydin Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Mr David Kenley 19,425,332 2.41%
    Citicorp Nominees Pty Limited 11,562,368 1.44%
    Jekl Holdings Pty Ltd <Kittel Property A/C> 9,500,000 1.18%
    Mr Andrew Morrison Stewart 9,233,176 1.15%
    Mr Anthony Shane Kittel & Mrs Michele Therese Kittel <Kittel Family Super A/C> 9,021,428 1.12%
    Dr Gavin James Shepherd & Mrs Catherine Shepherd <Tpj Superannuation Fund A/C> 8,000,000 0.99%
    Bnp Paribas Noms Pty Ltd <Drp> 6,214,909 0.77%
    Gavncath Pty Ltd <Shepherd Investment A/C> 6,050,000 0.75%
    Mr David Kenley <Kenley Super Plan A/C> 5,828,121 0.72%
    Boycecorp Pty Ltd <Boycecorp Discretionary A/C> 5,809,400 0.72%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 5,791,506 0.72%
    Mr Steven Yatomi-Clarke 5,790,647 0.72%
    Mr Madoc Tiong 5,550,000 0.69%
    Mr Richard Thomas Hayward Daly & Mrs Sarah Kay Daly <The Daly Family Super A/C> 4,898,738 0.61%
    Hsbc Custody Nominees (Australia) Limited 4,727,877 0.59%
    Dossman Pty Ltd 4,682,077 0.58%
    Mr Clinton Craig Hopper 4,632,798 0.58%
    Dr Rosamund Julian Banyard & Mr Phillip Stanley Holten <R Banyard Super Fund A/C> 4,473,570 0.55%
    Dr Vincent William Fitzgerald & Mrs Penelope Fitzgerald <Fitzgerald Super Fund A/C> 4,080,518 0.51%
    Golden Eggplant Pty Ltd <Golden Eggplant S/F A/C> 3,816,807 0.47%

    Profile

    since

    Note